Application of trans-astaxanthin in medicine for regulating ALPK1 protein expression

The invention provides an application of trans-astaxanthin in preparation of a medicine for regulating ALPK1 protein expression. The research determines that the astaxanthin microcapsule powder (the trans-astaxanthin content is 3%) can inhibit the expression level of ALPK1 protein in the kidney of a rat, is dose-dependent and has no damage to the liver and kidney of the rat; the invention not only provides a new application for the trans-astaxanthin, but also provides a new drug choice for an application scene needing to adjust the ALPK1 protein, and also has important guiding significance for preventing and treating ALPK1 related chronic diseases; and the trans-astaxanthin has no toxic or side effect, has no influence on kidney and liver functions, and has relatively high practical application value. 本发明提供了反式虾青素在制备调节ALPK1蛋白表达的药物中的应用。本发明研究确定了虾青素微囊粉(反式虾青素含量3％)能够抑制大鼠肾脏ALPK1蛋白的表达水平，并呈现剂量依赖性，及其对大鼠肝脏、肾脏无损伤的事实；本发明不仅为反式虾青素提供了新的用途，也为需要调节ALPK1蛋白的应用场景提供了新的药物选择，对于ALPK1相关慢性疾病的防治也具有重要的指导意义；且反式虾青素无毒副作用，对肾脏、肝脏功能无影响，具有较高的实际应